Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

The FDA Grants Breakthrough Therapy Designation To Merck And Daiichi Sankyo Partnered Ifinatamab Deruxtecan For Extensive-stage Small Cell Lung Cancer With Disease Progression On Or After Platinum-based Chemotherapy

Author: Benzinga Newsdesk | August 18, 2025 06:11am
  • Data from IDeate-Lung01 trial will be presented at upcoming IASLC 2025 World Conference on Lung Cancer
  • First Breakthrough Therapy Designation for Daiichi Sankyo and Merck's ifinatamab deruxtecan based on IDeate-Lung01 phase 2 trial, with support from IDeate-PanTumor01 phase 1/2 trial
  • Fourteenth Breakthrough Therapy Designation granted by FDA across the oncology portfolio of Daiichi Sankyo

Posted In: DSKYF DSNKY MRK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist